SP600125: Selective ATP-Competitive JNK Inhibitor for Pathway Dissection

Executive Summary: SP600125 is a reversible, ATP-competitive inhibitor of JNK1, JNK2, and JNK3 with IC₅₀ values of 40 nM, 40 nM, and 90 nM, respectively, under enzyme assay conditions (ApexBio). It displays >300-fold selectivity for JNK versus ERK1 and p38-2 kinases, confirmed in biochemical selectivity panels. In cell-based models, SP600125 inhibits c-Jun phosphorylation and downstream cytokine expression, including IL-2 and IFN-γ, at 5–10 μM in Jurkat T cells. It has been validated in pathways related to inflammation, apoptosis, and neural differentiation, with supporting evidence from multiple peer-reviewed studies (Eom et al. 2016). Proper usage and storage are critical for experimental reproducibility due to its solubility and stability profile.

Biological Rationale

The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) family. JNKs are key transducers of cellular stress signals, including UV radiation, cytokines, and DNA damage. They regulate transcriptional responses involved in apoptosis, inflammation, and cellular differentiation (Eom et al. 2016). Aberrant JNK signaling is implicated in cancer progression, neurodegenerative diseases, and immune disorders. Selective pharmacological inhibition of JNK is essential for mechanistic dissection of MAPK pathways and for developing targeted therapies (SP600125: Precision JNK Inhibition for Pathway Dissection…). This article extends the mechanistic focus of prior content by emphasizing application parameters and selectivity benchmarks.

Mechanism of Action of SP600125

SP600125 (dibenzo[cd,g]indazol-6(2H)-one; MW 220.23; C₁₄H₈N₂O; CAS 129-56-6) is a reversible, ATP-competitive inhibitor of JNK isoforms. In vitro, it binds the ATP-binding pocket of JNK1/2/3, with Ki = 190 nM (time-resolved fluorescence assay, GST-c-Jun substrate, recombinant human JNK2) (ApexBio). This competitive inhibition blocks phosphorylation of the c-Jun substrate, suppressing downstream transcriptional activity. SP600125 does not significantly inhibit ERK1 or p38-2 at concentrations up to 100 μM, supporting its selectivity for JNK among MAPK family kinases.

Evidence & Benchmarks

• SP600125 inhibits JNK1 and JNK2 with IC₅₀ = 40 nM, and JNK3 at 90 nM, measured in enzymatic assays using recombinant kinases (ApexBio).
• Displays >300-fold selectivity over ERK1 and p38-2, as determined by kinase profiling panels (ApexBio).
• Suppresses c-Jun phosphorylation in Jurkat T cells with cellular IC₅₀ of 5–10 μM (ApexBio).
• Reduces IL-2 and IFN-γ expression in T cells, indicating suppression of JNK-regulated cytokine transcription (ApexBio).
• In C17.2 neural stem-like cells, JNK inhibition by SP600125 blocks ionizing radiation-induced neuronal differentiation, implicating JNK in the PI3K-STAT3-mGluR1 pathway (Eom et al. 2016).
• Attenuates LPS-induced TNF-α production in mouse models, supporting its anti-inflammatory utility (ApexBio).

Applications, Limits & Misconceptions

SP600125 is widely used in apoptosis assays, inflammation research, and models of neurodegenerative disease. It is applied to dissect JNK-driven transcriptional programs and cytokine responses. The compound is also used in studies of cancer, where JNK signaling modulates proliferation and apoptotic sensitivity (SP600125: Unraveling JNK Inhibition for Precision Disease…). This article clarifies quantitative selectivity and solubility parameters not fully addressed previously.

Common Pitfalls or Misconceptions

• SP600125 is not a pan-MAPK inhibitor; it is highly selective for JNK isoforms versus ERK or p38 kinases.
• Cellular IC₅₀ (5–10 μM) is much higher than enzymatic IC₅₀ (nM range); dosing must be adjusted for cell-based versus biochemical assays.
• SP600125 is insoluble in water; improper dissolution can cause experimental failure. DMSO or ethanol (with gentle warming) are required for stock solutions.
• Long-term storage of solutions at room temperature decreases potency. Stocks should be freshly prepared or stored at ≤ –20°C.
• Off-target effects may occur at high concentrations; results should be interpreted within the selectivity window.

Workflow Integration & Parameters

SP600125 is typically supplied as a solid and must be dissolved to ≥11 mg/mL in DMSO or ≥2.56 mg/mL in ethanol with warming. For cell-based experiments, working concentrations of 5–20 μM are common; for in vitro kinase assays, 50–500 nM is typical. Solutions should be freshly prepared; for longer storage, aliquots at –20°C are recommended. SP600125 is compatible with apoptosis, cytokine, and phosphoproteomic workflows (SP600125: A Next-Generation JNK Inhibitor for Phosphoprot…). This article updates prior workflows by specifying validated solubility and storage parameters.

Conclusion & Outlook

SP600125 remains a gold standard for selective JNK inhibition in research on apoptosis, inflammation, and neural signaling. Its validated selectivity, reproducibility, and versatility across models underpin its widespread adoption. Future directions include integration with high-throughput kinase profiling and combinatorial pathway inhibition. For detailed protocols and ordering, refer to the SP600125 product page (A4604 kit).